IDNA:NYE-iShares Genomics Immunology and Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 19.91

Change

-0.48 (-2.35)%

Market Cap

USD 0.12B

Volume

0.09M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-03 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+5.78 (+4.35%)

USD 37.98B
FHLC Fidelity® MSCI Health Care In..

+2.97 (+4.79%)

USD 2.70B
FXH First Trust Health Care AlphaD..

+5.91 (+6.31%)

USD 1.01B
XHE SPDR® S&P Health Care Equipme..

+5.37 (+7.42%)

USD 0.18B
SBIO ALPS Medical Breakthroughs ETF

+1.69 (+7.16%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

+4.54 (+4.88%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

+2.01 (+8.33%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

+2.46 (+4.86%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+1.14 (+8.06%)

USD 0.01B
IHF iShares U.S. Healthcare Provid..

+1.97 (+3.78%)

N/A

ETFs Containing IDNA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -12.02% 19% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.02% 19% F 24% F
Trailing 12 Months  
Capital Gain -13.70% 14% F 22% F
Dividend Return 0.48% 44% F 7% C-
Total Return -13.22% 14% F 20% F
Trailing 5 Years  
Capital Gain -24.04% 10% F 11% F
Dividend Return 3.49% 53% F 6% D-
Total Return -20.55% 10% F 9% A-
Average Annual (5 Year Horizon)  
Capital Gain -8.92% 5% F 7% C-
Dividend Return -8.36% 5% F 6% D-
Total Return 0.56% 53% F 14% F
Risk Return Profile  
Volatility (Standard Deviation) 26.76% 14% F 38% F
Risk Adjusted Return -31.25% 5% F 8% B-
Market Capitalization 0.12B 60% D- 29% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.